Methods for producing aglycones from steroidal alkaloid glycosides, compositions containing aglycones from steroidal alkaloid glycosides, and novel lactic acid bacteria
Lactic acid bacteria convert steroid alkaloid glycosides to aglycones in a simple and efficient process, addressing the complexity of existing methods and enabling their use in food, beverages, and pharmaceuticals.
Patent Information
- Application Number
- JP2024062095
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-25
- Filing Date
- 2024-04-08
- Publication Date
- 2024-11-07
AI Technical Summary
Existing methods for converting steroid alkaloid glycosides like tomatine to their aglycones, such as tomatidine, are complex, time-consuming, and limited in application due to the use of hydrochloric acid, which complicates their use in food and drink products.
A method involving lactic acid bacteria, particularly those from the genera Pediococcus and Levilactobacillus, is used to ferment steroid alkaloid glycosides in processed tomato products, converting them to their aglycones without the need for added acid, and the resulting aglycones can be used directly in food, beverages, and pharmaceuticals.
This method efficiently converts steroid alkaloid glycosides to their aglycones, enabling their use in food, beverages, and pharmaceuticals, leveraging their physiologically active properties like lowering cholesterol and inhibiting arteriosclerosis.
Smart Images

Figure 2024157522000004 
Figure 2024157522000005 
Figure 2024157522000006
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing an aglycone of a steroid alkaloid glycoside, and more specifically, to a method for simply and efficiently producing the aglycone from a steroid alkaloid glycoside using a lactic acid bacterium capable of converting the steroid alkaloid glycoside into its aglycone, a composition containing the obtained aglycone of a steroid alkaloid glycoside and the lactic acid bacterium, a novel lactic acid bacterium, etc. [Background technology]
[0002] Tomato fruits contain steroid alkaloid glycosides such as tomatine and esculoside A, and tomatine is particularly abundant in tomato flowers, stems, leaves, and unripe fruits. These steroid alkaloid glycosides, such as tomatine, have a similar chemical structure to solanine, which is contained in potatoes, which are also members of the Solanaceae family, and are known to have bactericidal and insect repellent properties and to be toxic to mammals.
[0003] In contrast, there are no reported toxicity reports for tomatidine, the aglycone of tomatine, and it has been reported to have physiologically active effects such as lowering blood cholesterol and inhibiting arteriosclerosis (Patent Document 1), reducing muscle atrophy (Patent Document 2), having antidepressant effects (Patent Document 3), and inhibiting rough skin (Patent Document 4).
[0004] Esculeoside A, which has been confirmed to have an inhibitory effect against arteriosclerosis, is found in large amounts in mature tomatoes and is produced from tomatine during the ripening process of tomatoes (Non-Patent Documents 1 and 2). It has been reported that esculeogenin A, the aglycone of esculoside A, exhibits a stronger inhibitory effect against arteriosclerosis (Non-Patent Document 1). Furthermore, esculoside A is converted to esculoside B-1 and B-2 by heat (Non-Patent Document 3).
[0005] As a method for producing an aglycone from a steroid alkaloid glycoside, for example, a chemical method for producing tomatidine from tomatine, a method has been proposed in which tomatine is extracted from processed tomatoes, a hydrochloric acid solution is added thereto to convert the tomatine to tomatidine by hydrolysis, and tomatidine is recovered (Patent Document 4, Patent Document 5).
[0006] On the other hand, some plant pathogens are known to have an enzyme (tomatinase) that decomposes tomatine and eliminates its fungicidal activity (Non-Patent Document 4). However, to the best of the present inventors' knowledge, there have been no reports of a method for producing aglycones from steroid alkaloid glycosides using microorganisms such as lactic acid bacteria, for example, a method for producing tomatidine from tomatine. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] JP 2009-209099 A [Patent Document 2] Patent No. 6175172 [Patent Document 3] JP 2022-53441 A [Patent Document 4] JP 2019-210236 A [Patent Document 5] JP 2018-184394 A [Non-patent literature]
[0008] [Non-Patent Document 1] Yuuki Tominaga, Ryuji Nagai, "Research results on esculoside A contained in tomatoes ~ The relationship between the mechanism of arteriosclerosis and tomatoes ~" Topic (Vegetable Information, March 2020) https: / / www.alic.go.jp / content / 001174574.pdf [Non-Patent Document 2] Takao Yamanaka et al., “C22 Isomerization in α-Tomatine-to-Esculeoside A Conversion during Tomato Ripening Is Driven by C27 Hydroxylation of Triterpenoidal Skeleton”, J. Agric. Food Chem. 2009,57, 3786-3791 [Non-Patent Document 3] Hideyuki Manabe at al., “Saponins Esculeosides B-1 and B-2 in Italian Canned Tomatoes”, Chem. Pharm. Bull. 61(7) 764-767 (2013) [Non-Patent Document 4] Seipke, RF; Loria, R. (2008). “Streptomycess cabies 87-22 Possesses a Functional Tomatinase”. Journal of Bacteriology 190 (23): 7684-7692 Summary of the Invention [Problem to be solved by the invention]
[0009] As described above, tomatidine is a useful physiologically active substance; however, converting toxic tomatine into tomatidine requires many steps and is time-consuming, and hydrochloric acid is added for hydrolysis, which inevitably limits the use of the resulting product in foods, beverages, and the like.
[0010] An object of the present invention is to provide a method for producing an aglycone of a steroid alkaloid glycoside in a simple and industrially efficient manner, and to provide a composition containing an aglycone of a steroid alkaloid glycoside which can be used in foods and beverages. [Means for solving the problem]
[0011] As a result of intensive research to solve the above problems, the present inventors have found that by subjecting a processed tomato product containing the steroid alkaloid glycoside tomatine, for example, a processed product of unripe tomato fruits (hereinafter sometimes referred to as "unripe tomatoes"), to fermentation with lactic acid bacteria (hereinafter sometimes referred to as "lactic acid fermentation"), tomatine can be efficiently converted to tomatidine, and the obtained tomatidine-containing composition can be used as is in foods and beverages. They have also found that by heating the processed product without adding acid, tomatine can be converted to tomatidine. The present invention was achieved based on these findings.
[0012] That is, the present invention is as follows. (1) A method for producing an aglycone of a steroid alkaloid glycoside, which comprises allowing a lactic acid bacterium having the ability to convert a steroid alkaloid glycoside into its aglycone, or a processed product thereof, to act on a steroid alkaloid glycoside to produce the aglycone. (2) The method for producing according to (1) above, wherein the steroid alkaloid glycoside is tomatine and the aglycone of the steroid alkaloid glycoside is tomatidine. (3) The production method according to (1) or (2) above, wherein the lactic acid bacteria are either or both of lactic acid bacteria belonging to the genus Pediococcus or lactic acid bacteria belonging to the genus Levilactobacillus. (4) A composition comprising either live or killed lactic acid bacteria or both of the bacteria having the ability to convert a steroid alkaloid glycoside into its aglycone, and the aglycone of a steroid alkaloid glycoside. (5) The steroid alkaloid glycoside is tomatine, the aglycone of the steroid alkaloid glycoside is tomatidine, the content of the tomatidine in the composition is 0.01 to 10% or more in terms of dry mass, and the content of lactic acid bacteria in the composition is 1 x 10 per 1 g of dry mass. 13 ~1×10 6 The composition according to (4) above, (6) The composition according to (4) or (5) above, wherein the lactic acid bacteria are either or both of lactic acid bacteria belonging to the genus Pediococcus or lactic acid bacteria belonging to the genus Levilactobacillus. (7) A food, drink, cosmetic, or pharmaceutical comprising the composition according to any one of (4) to (6) above. (8) A method for producing tomatidine, comprising heating processed tomatoes in an aqueous medium without adding an acid. (9) Leviractobacillus sp. NC4 strain, deposited under accession number NITE P-03879.
[0013] In another aspect of the present invention, there is provided a food or beverage comprising an aglycone of a steroid alkaloid glycoside or a composition containing the same, which food or beverage is indicated to prevent or ameliorate a disease or condition by administration of the aglycone of a steroid alkaloid glycoside. Effect of the Invention
[0014] The production method of the present invention can efficiently convert steroid alkaloid glycosides into their aglycones (e.g., tomatine to tomatidine, esculeoside to esculeogenin). As described above, tomatidine and esculeogenin have useful physiologically active effects, and the aglycones of the steroid alkaloid glycosides of the present invention or compositions containing them (e.g., tomatidine or a tomatidine-containing composition, esculeogenin or an esculeogenin-containing composition) can be used in foods and beverages, cosmetics, pharmaceuticals, etc. [Brief description of the drawings]
[0015] [Figure 1] 1 is a micrograph showing the morphology of the lactic acid bacterium Levilactobacillus sp. NC4 (NITE P-03879) of the present invention. [Diagram 2] FIG. 1 shows the results of a fermentation test (sugar assimilation test) using unripe tomatoes with 18 species of lactic acid bacteria. [Diagram 3] FIG. 1 shows the transition of pH when NB17, NC4, and a mixture of NB17 and NC4 were cultured for 0 to 72 hours. [Figure 4] FIG. 1 shows the transition of tomatidine content during 0 to 72 hour culture of NB17, NC4, and a mixture of NB17 and NC4. [Diagram 5] FIG. 1 shows the change in pH over time when a mixed bacterium of NB17 and NC4 was cultured for 0 to 48 hours. [Figure 6] FIG. 1 shows the change in tomatidine content over time when a mixed bacterium of NB17 and NC4 was cultured for 0 to 48 hours. [Figure 7] FIG. 1 shows the tomatidine content in processed unripe tomatoes after heating for 30 and 60 minutes. [Figure 8] 1 is a chart showing a chromatogram (measurement results) of tomatidine 1000 μg / ml. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The following describes in detail an embodiment of the present invention, but the following description is merely an example of an embodiment of the present invention, and the present invention is not limited to the following description. In this specification, the expression "~" is used to include the numerical value or physical property value before and after it. In addition, % (percent) means mass (wt) % unless otherwise specified.
[0017] (Steroid alkaloid glycosides) In the present invention, steroidal alkaloid glycosides refer to compounds in which a sugar residue is bound to a steroid skeleton having a nitrogen atom.
[0018] Examples of steroid alkaloid glycosides include tomatine (a compound represented by formula (I); reprinted from Wikipedia; https: / / ja.wikipedi a.org / wiki / %E3%83%88%E3%83%9E%E3%83%81%E3%83%B3), esculeoside A (a compound represented by formula (II); reprinted from Chem.Pharm. Bull. 61(7) 764-767 (2013)), esculeoside B-1 (a compound represented by formula (III); reprinted from Chem.Pharm. Bull. 61(7) 764-767 (2013)), and esculeoside B-2. In addition, esculeoside B-1 and B-2 are compounds with different absolute configurations of carbons at the 22nd and 23rd positions (B-1: 22R, 23S, B-2: 22S, 23R). In the present invention, esculeoside A, B-1 and B-2 may be collectively referred to as "esculeoside".
[0019] Examples of the aglycone of steroid alkaloid glycosides include the aglycone of tomatine, the aglycone of esculoside A, the aglycone of esculoside B-1, and the aglycone of esculoside B-2, and more specifically, tomatidine, esculeogenin A, esculeogenin B-1, esculeogenin B-2, etc. In the present invention, esculeogenins A, B-1, and B-2 may be collectively referred to as "esculeogenin".
[0020] [ka]
[0021] [ka]
[0022] [ka]
[0023] (Raw material steroid alkaloid glycoside) In a preferred embodiment of the present invention, the steroid alkaloid glycoside used as the raw material may be a synthetic product, a natural product, or a processed product of a natural product. For example, tomatine and esculoside are contained in plant bodies such as flowers, stems and leaves, and unripe fruits of tomatoes, and it is preferable to use processed products of these, particularly processed products of unripe tomatoes for tomatine and processed products of ripe tomatoes for esculoside, as the raw material.
[0024] Here, tomato (Solanum lycopersicum L.) is a plant of the genus Solanum in the family Solanaceae, and may be any variety of plant as long as it contains tomatine and esculeoside. In the present invention, when tomatine is used as a raw material, tomato flowers, stems and leaves, and unripe fruits are preferred, and unripe tomatoes are particularly preferred. When esculeoside is used as a raw material, mature tomato fruits are preferred.
[0025] Examples of processed tomatoes include juice, crushed products, shredded products, dried products, roasted products, extracts, powdered products, and frozen products of tomato flowers, stems, leaves, and unripe tomatoes, as well as processed products such as squeezed juice, dried powdered products, dried products, crushed and filtered products (puree, juice), shredded products, hot water extracts, canned products, and combinations of these.
[0026] (lactic acid bacteria) The lactic acid bacteria used in the present invention are not particularly limited as long as they have the ability to convert steroid alkaloid glycosides to their aglycones (e.g., the ability to convert tomatine to tomatidine, and the ability to convert esculeoside to esculeogenin). Here, lactic acid bacteria is a general term for bacteria that have the ability to ferment sugars to obtain energy and produce a large amount of lactic acid, and are defined as bacteria that are Gram-stain positive, do not possess catalase, are facultatively anaerobic, are neither motile nor have endospores, and produce 50% or more of lactic acid based on the glucose consumed (Lactic Acid Bacteria Experiment Manual - From Isolation to Identification, Asakura Publishing, February 25, 1992). However, in the present invention, even if they do not simultaneously satisfy all of these properties, so-called lactic acid bacteria in the broad sense are not particularly limited as long as they have the ability to convert steroid alkaloid glycosides to their aglycones (e.g., the ability to convert tomatine to tomatidine, and the ability to convert esculeoside to esculeogenin).
[0027] Tomatine is a compound represented by formula (I), which is a compound in which one galactose, two glucoses, and one xylose are bound to tomatidine. Esculeside is a compound represented by formula (II) or formula (III), which is a compound in which one galactose, two glucoses, and one xylose are bound to esculeogenin A and esculeogenin B-1, respectively, and one glucose is further bound to them. In order to produce tomatidine from tomatine, or to produce esculeogenin A or esculeogenin B-1 from esculeside, these sugars must be cleaved by hydrolysis.
[0028] The lactic acid bacteria in the present invention are preferably those capable of assimilating at least one type of sugar selected from these sugars (galactose, glucose, xylose), more preferably those capable of assimilating at least two types of sugars, for example glucose and galactose, and even more preferably those capable of assimilating three types of sugars.
[0029] As specifically shown in the Examples described below, the lactic acid bacteria of the present invention can efficiently convert tomatine to tomatidine. As described above, tomatine and esculoside are similarly glycosylated compounds with three types of sugars. Therefore, it is considered that lactic acid bacteria having the ability to cleave sugars bound to tomatine also have the ability to cleave sugars bound to esculeogenin.
[0030] Specific examples of lactic acid bacteria in the present invention include lactic acid bacteria belonging to the following genera:
[0031] Levilactobacillus genus; e.g., L. brevis
[0032] Lactobacillus genus; e.g., L. acidophilus, L. gasseri, L. delbrueckii subsp. bulgaricus, L. helveticus
[0033] Genus Weissella; e.g., W. confusa, W. cibaria
[0034] Genus Leuconostoc; e.g., L. mesenteroides, L. mesenteroides subsp. cremoris, L. mesenteroides subsp. dextranicum, L. mesenteroides subsp. mesenteroides, L. citreum, L. garlicum
[0035] Genus Pediococcus; e.g., P. pentosaceus, P. acidilactici, P. cellicola
[0036] Streptococcus genus; e.g., S. thermophilus
[0037] Enterococcus genus; e.g., E. faecalis
[0038] Tetragenococcus genus; e.g., T. halophilus
[0039] Genus Bifidobacterium; e.g., B. bifidum, B. breve, B. animalis subsp. lactis, B. longum
[0040] Genus Lactiplantibacillus; e.g., L. plantarum, L. plantarum subsp. plantarum, L. pentosus
[0041] Genus Lactococcus; e.g., L. lactis subsp. cremoris, L. lactis subsp. tructae, L. lactis, L. lactis subsp. hordnie, L. lactis subsp. lactis
[0042] Genus Lacticaseibacillus; e.g., L. casei, L. paracasei, L. paracasei subsp. paracasei, L. paracasei subsp. tolerans
[0043] Genus Latilactobacillus; e.g., L. sakei, L. sakei subsp. carnosus, L. sakei subsp. sakei, L. curvatus
[0044] Specific strains of these lactic acid bacteria include, for example, the following lactic acid bacteria listed in the catalog of the National Institute of Technology and Evaluation (NITE) Biotechnology Center (NBRC) or deposited at the NITE Patent Microorganisms Depositary Center.
[0045] Lactobacillus brevis (NBRC3345, NBRC3960, NBRC12005, NBRC12520, NBRC13109, NBRC13110, NBRC107147, NBRC115323, NBRC115324, NBRC115325) Leviractobacillus sp.NC4 (NITE P-03879)
[0046] Lactobacillus acidophilus (L. acidophilus) NBRC13951 Lactobacillus delbrueckii subsp. bulgaricus NBRC13953
[0047] Lactobacillus helveticus (NBRC3809, NBRC15019)
[0048] Weissella confusa (NBRC3955, NBRC3957, NBRC3958, NBRC106469) Weissella cibaria (W. cibaria) NBRC106073
[0049] Leuconostoc mesenteroides (NBRC110676, NBRC114781, NBRC115205)
[0050] Leuconostoc mesenteroides subsp. Cremoris (NBRC102479, NBRC107766) Leuconostoc mesenteroides subsp. Dextranicum NBRC3349, NBRC100495 Leuconostoc mesenteroides subsp. mesenteroides (NBRC3832, NBRC12060, NBRC100496) Leuconostoc garlicum (L. garlicum) HFPRC9111 (FERM P-20952)
[0051] Leuconostoc citreum (NBRC102476, NBRC113243, NBRC115213, NBRC115214, NBRC115215, NBRC115216)
[0052] Pediococcus pentosaceus (NBRC3182, NBRC3891, NBRC3892, NBRC3893, NBRC3894, NBRC12229, NBRC12230, NBRC12232, NBRC12318, NBRC101982, NBRC101983, NBRC101984, NBRC101985, NBRC101986, NBRC101987, NBRC107768, NBRC111689, NBRC111717, NBRC115212, Pediococcus pentosaceus (HFPRC9101 (FERM P-20897)
[0053] Pediococcus acidilactici (NBRC3076, NBRC3885, NBRC3888, NBRC12218, NBRC12231, NBRC109619, NBRC111694, NBRC111695, NBRC111696, NBRC111697, NBRC111698, NBRC111701) , NBRC111702, NBRC111703, NBRC111704, NBRC111706, NBRC111707, NBRC111708, NBRC111709 , NBRC111710, NBRC111711, NBRC111712, NBRC111713, NBRC111714, NBRC111715, NBRC111716
[0054] Pediococcus cellicola (P. cellicola) NBRC106103 Pediococcus sp.KB1 (NITE P-755)
[0055] Streptococcus thermophilus (S. thermophilus) NBRC13957, NBRC111149
[0056] Enterococcus faecalis (NBRC3971, NBRC3989, NBRC12580, NBRC12964, NBRC12965, NBRC12966, NBRC12967, NBRC12968, NBRC12969, NBRC12970, NBRC100480, NBRC100481, NBRC100482, NBRC100483, NBRC100484)
[0057] Tetragenococcus halophilus (NBRC12172, NBRC109726, NBRC109727)
[0058] Tetragenococcus halophilus subsp. Flandriensis NBRC114546
[0059] Tetragenococcus halophilus subsp. halophilus NBRC100498
[0060] Bifidobacterium bifidum (B. bifidum) NBRC100015 Bifidobacterium breve (B. breve) NBRC115160 Bifidobacterium longum (B. longum) NBRC114370, NBRC114494
[0061] Lactococcus cremoris subsp. torcuta (L. lactis subsp. tructae) NBRC110453
[0062] Lactococcus lactis (NBRC114780, NBRC115162, NBRC115206) Lactococcus lactis subsp. hordnie NBRC100931
[0063] Lactococcus lactis subsp. lactis NBRC12007, NBRC100933, NBRC114714, NBRC114784
[0064] Lacticaceae Bacillus casei (L. casei) NBRC15883, NBRC101979, NBRC101980, NBRC101981
[0065] Bacillus paracasei (L. paracasei) NBRC111693, NBRC114778, NBRC114779, NBRC115701, NBRC115702
[0066] L. paracasei subsp. paracasei NBRC3533, NBRC3953, NBRC12004, NBRC14709, NBRC15889
[0067] Lacticacei Bacillus paracasei subsp. tolerans NBRC15906
[0068] Lathyractobacillus sakei (NBRC3541, NBRC107130) Lathyractobacillus sakei subsp. carnosus NBRC107868 Lactobacillus sakei subsp. sakei 15893
[0069] Lathyractobacillus curvatus (NBRC12456, NBRC15884, NBRC107129, NBRC113825)
[0070] Among these lactic acid bacteria, for example, lactic acid bacteria belonging to the genera Pediococcus and Levilactobacillus are preferred. Specific examples of the strains include Pediococcus pentosaceus HFPRC9101 (FERM P-20897) (hereinafter sometimes referred to as "NB17") and Levilactobacillus sp. NC4 (NITE P-03879) (hereinafter sometimes referred to as "NC4"). These strains have been deposited at the NITE Patent Microorganisms Depositary Center under the above accession numbers.
[0071] Here, the above-mentioned NC4 is a novel lactic acid bacteria strain isolated by the present inventors. Its morphology (microscopic photograph) is shown in Figure 1, and its bacteriological properties are shown below.
[0072] Cell morphology Bacillus No spore formation Gram stain positive Motile Non-motile Catalase reaction: negative Growth at 15℃ Good growth Growth at 45℃ No growth Gas production from glucose Positive Initial pH: Can grow at pH 6
[0073] Sugar assimilation (positive: +, negative: -, weakly positive: w) (30℃, 3 days culture) Mannitol (-) Mannose (-) Lactose (w) Fructose (+) Cellobiose (-) Melibiose (+) Melezitose (-) Raffinose (w) Maltose (+) Ribose (+) Sorbitol (-) Rhamnose (-) Trehalose (-) L-Arabinose (+) Salicin (-) Gluconate (-) Sucrose (w) Esculin (w)
[0074] These lactic acid bacteria may be used alone or in combination of genera or species. The genera or species of lactic acid bacteria to be combined are not particularly limited, and may be selected from any genera or species. Among them, a combination of lactic acid bacteria belonging to the genus Pediococcus and the genus Levilactobacillus is preferred, and more specifically, for example, a combination of NB17 and NC4 is more preferred.
[0075] In addition, the above-mentioned lactic acid bacteria can be mutated by mutation means using ultraviolet light, X-rays, chemicals, etc., or by transformation through genetic recombination, and such mutant strains (mutated lactic acid bacteria) can also be used as the lactic acid bacteria in the present invention as long as they have the activity of converting steroid alkaloid glycosides into their aglycones. Furthermore, lactic acid bacteria present in nature, such as animals and plants, may be used by simply adjusting the conditions for lactic acid fermentation.
[0076] (Cultivation of lactic acid bacteria) In the present invention, it is preferable to previously culture the lactic acid bacteria and use the culture for converting steroid alkaloid glycosides to their aglycones. That is, the lactic acid bacteria used in the present invention are cultures of the lactic acid bacteria.
[0077] The culture conditions for lactic acid bacteria are not particularly limited as long as they allow the lactic acid bacteria to be cultured, but it is preferable to culture the bacteria in a medium with a pH of about 6.0 to 7.0, at a culture temperature of 30 to 40° C., for 1 to 3 days. As the culture medium for lactic acid bacteria, any medium that is commonly used for culturing lactic acid bacteria can be used, and for example, a natural medium or a synthetic medium containing a carbon source, a nitrogen source, inorganic salts, and other nutrients can be used. Examples of the form of the medium include a liquid medium, a semi-liquid medium, and a solid medium.
[0078] Examples of carbon sources include carbohydrates and sugar alcohols such as glucose, fructose, sucrose, mannose, maltose, mannitol, xylose, galactose, starch, molasses, sorbitol, and glycerin; organic acids such as acetic acid, citric acid, lactic acid, fumaric acid, maleic acid, and gluconic acid; and alcohols such as ethanol and propanol. Carbon sources may be used alone or in combination of two or more. The concentration of these carbon sources in the medium is usually about 0.1 to 10%.
[0079] Examples of the nitrogen source include nitrogen compounds, such as inorganic or organic ammonium compounds, such as ammonium chloride, ammonium sulfate, ammonium nitrate, and ammonium acetate, urea, aqueous ammonia, sodium nitrate, and potassium nitrate. In addition, nitrogen-containing organic compounds, such as corn steep liquor, meat extract, peptone, NZ-amine, protein hydrolysates, and amino acids, can also be used. The nitrogen source may be used alone or in combination of two or more. The concentration of the nitrogen source in the medium varies depending on the nitrogen compound used, but is usually about 0.1 to 10%.
[0080] Examples of inorganic salts include potassium dihydrogen phosphate, potassium dihydrogen phosphate, magnesium sulfate, iron sulfate, sodium chloride, ferrous nitrate, manganese sulfate, zinc sulfate, cobalt sulfate, and calcium carbonate. These inorganic salts may be used alone or in combination of two or more. The concentration of inorganic salts in the medium varies depending on the inorganic salt used, but is usually about 0.01 to 1.0%.
[0081] Examples of the nutrient substances include meat extract, peptone, polypeptone, yeast extract, dry yeast, corn steep liquor, skim milk powder, hydrolyzed defatted soybean with hydrochloric acid, or extracts of animals, plants or microbial cells or their decomposition products, etc. The concentration of the nutrient substance in the medium varies depending on the nutrient substance used, but is usually about 0.1 to 10%.
[0082] The pH of the medium is adjusted with an inorganic acid or alkali solution, an organic acid or alkali solution, ammonia, a pH buffer solution, or the like.
[0083] (Processed lactic acid bacteria) The lactic acid bacteria culture of the present invention is a culture (including the lactic acid bacteria itself) that is used in the presence of a steroid alkaloid glycoside (e.g., tomatidine, esculeogenin) to produce an aglycone of the steroid alkaloid glycoside from the compound (e.g., tomatine, esculeside). In the present invention, preferred examples of the lactic acid bacteria culture include a culture liquid, wet cells separated from the culture supernatant, a liquid in which the cells are suspended, dried cells obtained by freeze-drying or acetone treatment, immobilized lactic acid bacteria in which the cells are bound to a carrier, and culture supernatant. In the present invention, these are referred to as processed products of lactic acid bacteria.
[0084] (Production of aglycones of steroid alkaloid glycosides) The method for producing an aglycone of a steroid alkaloid glycoside of the present invention is characterized in that a lactic acid bacterium having an ability to convert a steroid alkaloid glycoside to its aglycone (e.g., ability to convert tomatine to tomatidine, ability to convert esculeside to esculeogenin) or a processed product thereof is allowed to act on a steroid alkaloid glycoside to produce its aglycone (e.g., acting on tomatine to produce tomatidine, acting on esculeside to produce esculeogenin). Here, "acting on a steroid alkaloid glycoside" means culturing the lactic acid bacterium or a processed product thereof in a medium or aqueous medium containing a steroid alkaloid glycoside (e.g., tomatine, esculeside) or contacting the lactic acid bacterium with a steroid alkaloid glycoside (e.g., tomatine, esculeside) to produce its aglycone (e.g., tomatidine, esculeogenin).
[0085] The method of allowing the lactic acid bacteria or a processed product thereof to act on a steroid alkaloid glycoside may be any condition or method as long as the steroid alkaloid glycoside (e.g., tomatine, esculoside) is contacted with the lactic acid bacteria or a processed product thereof to produce an aglycone of the steroid alkaloid glycoside (e.g., tomatidine, esculeogenin). Specifically, for example, processed tomatoes are suspended in an appropriate liquid medium, which is heat-sterilized and cooled, and then the lactic acid bacteria are added to the medium, the pH and nutrients of which have been adjusted as necessary, and the medium is cultured, preferably with stirring. This allows the aglycone (e.g., tomatidine from tomatine, esculeogenin from esculoside) to be produced from the steroid alkaloid glycoside.
[0086] In the above, the term "culture" includes not only culture of lactic acid bacteria having the ability to grow, but also culture of processed lactic acid bacteria such as immobilized lactic acid bacteria and lactic acid bacteria that cannot grow. In addition, the medium containing the obtained aglycone of the steroid alkaloid glycoside (e.g., tomatidine, esculeogenin) may be collectively referred to as a "culture."
[0087] In the present invention, processed tomatoes may be subjected to lactic acid fermentation under conditions that allow naturally occurring lactic acid bacteria to multiply, thereby producing aglycones from steroid alkaloid glycosides (e.g., tomatidine from tomatine, and esculeogenin from esculoside).
[0088] The conditions for heat sterilization of processed tomato products are not particularly limited, but they may be heated usually at 60 to 121° C., preferably 70 to 90° C., for usually 15 to 120 minutes, preferably 30 to 60 minutes.
[0089] The reaction conditions are not particularly limited as long as lactic acid fermentation is possible, and the pH is usually about 3.5 to 7.0, preferably about 4.0 to 6.5, the temperature is usually about 20 to 70° C., preferably about 30 to 40° C., and the reaction time is usually about 8 to 72 hours, preferably about 16 to 32 hours. Aeration is not particularly required during the reaction, and either anaerobic or aerobic conditions may be used, with anaerobic conditions being preferred.
[0090] The above-mentioned method can convert all of the steroid alkaloid glycosides contained in the processed tomatoes into their aglycones. Here, "all of the steroid alkaloid glycosides" means that, for example, when the steroid alkaloid glycoside is tomatine, the tomatine content in the processed tomatoes is equal to or less than the tomatine content in fully ripe tomatoes.
[0091] Furthermore, the present inventors have found through their studies that tomatidine can be produced from tomatine during heat sterilization of processed tomatoes.
[0092] Thus, according to another aspect of the present invention there is provided a process for the preparation of tomatidine, characterized in that processed tomatoes, preferably processed unripe tomatoes, are heated in an aqueous medium without the addition of an acid.
[0093] Even if the processed tomato products remain at their initial pH, by heating them in an aqueous medium, the conditions for hydrolysis of tomatine to tomatidine are created, and by heating the processed tomato products for a longer period of time, all of the tomatine can be converted to tomatidine.
[0094] The aqueous medium may be water to which no acid has been added. The heating temperature may be the same as the heat sterilization temperature, and the heating time may be generally about 10 to 180 minutes, preferably about 20 to 90 minutes, and more preferably about 30 to 60 minutes.
[0095] (Steroidal alkaloid glycoside aglycone-containing composition) The culture or heated product of processed tomatoes (hereinafter sometimes referred to as "reaction liquid") can be used as it is as a composition containing an aglycone of a steroid alkaloid glycoside, for example, a tomatidine or esculeogenin-containing composition (hereinafter sometimes simply referred to as "composition"). However, if necessary, the composition can be sterilized, concentrated or dried and then used as the composition. The sterilization conditions may be the same as those for the heat sterilization of the processed tomatoes.
[0096] Concentration and drying of the reaction solution may be carried out by a method known per se and commonly used for food production, with the addition of excipients, etc., as necessary. For example, when powdering by spray drying, dextrin may be added. The amount of dextrin added is not particularly limited as long as it is an amount that can be powdered.
[0097] The composition of the present invention contains at least the aglycone of a steroid alkaloid glycoside (e.g., tomatidine, esculeogenin) and either live or killed lactic acid bacteria capable of converting the steroid alkaloid glycoside to its aglycone (e.g., tomatidine, esculegenin), and includes compositions in any form (e.g., solid, semi-solid, liquid, powder), but for long-term storage, a powder composition (lyophilized powder) is preferred. Note that such killed bacteria usually no longer have the ability to convert the steroid alkaloid glycoside to its aglycone.
[0098] In the composition of the present invention, the content of the aglycone of the steroid alkaloid glycoside (e.g., tomatidine, esculogenin) is, in terms of dry mass (hereinafter the same), usually 0.01% or more, preferably 0.1% or more, more preferably 0.5% or more, and usually 10% or less, preferably 6% or less, more preferably 4% or less.
[0099] The lactic acid bacteria contained in the composition of the present invention may be live or dead bacteria, or may be both. The content is 1×10 13 ~1×10 6 / g, preferably 1×10 12 ~1×10 7 / g, more preferably 1×10 11 ~1×10 8 Pieces / g.
[0100] The composition of the present invention usually contains a tomato-derived component other than the aglycone of a steroid alkaloid glycoside, such as tomatidine or esculeogenin. The lower limit of the content of the tomato-derived component is usually 10% or more, preferably 25% or more, more preferably 40% or more, and the upper limit is usually 90% or less, preferably 75% or less, more preferably 60% or less.
[0101] The composition of the present invention may also contain an excipient such as dextrin that has been added during powderization by spray drying, etc. The lower limit of the content of the excipient, for example, dextrin, is usually 10% or more, preferably 25% or more, more preferably 40% or more, and the upper limit is usually 90% or less, preferably 75% or less, more preferably 60% or less.
[0102] (Separation and purification of aglycones of steroid alkaloid glycosides) The aglycone of the steroid alkaloid glycoside can be obtained from the resulting reaction solution by a known method, for example, removing the precipitate and adjusting the pH as necessary, extracting the aglycone of the steroid alkaloid glycoside (e.g., tomatidine, esculeogenin) with an appropriate solvent, preferably a lower alcohol such as ethanol, and purifying it by column chromatography, etc., as necessary.
[0103] Here, in the present invention, the aglycone of a steroid alkaloid glycoside (e.g., tomatidine, esculeogenin) contained in the composition, or purified tomatidine or esculeogenin, may be a pharmacologically acceptable salt, and the aglycone of a steroid alkaloid glycoside means one including such salts.
[0104] (Application) As described above, the aglycones of steroid alkaloid glycosides, such as tomatidine, have various physiologically active effects such as lowering blood cholesterol, inhibiting arteriosclerosis, reducing muscle atrophy, having antidepressant effects, and inhibiting rough skin. Ingestion or administration of tomatidine is expected to reduce the risk of, prevent, or improve these diseases or conditions (symptoms).
[0105] Furthermore, as described above, esculeogenin has an inhibitory effect against arteriosclerosis, and it is expected that the ingestion or administration of esculeogenin will reduce the risk of, prevent, or improve these diseases or conditions (symptoms). Therefore, the composition of the present invention containing the aglycone of a steroid alkaloid glycoside such as tomatidine or esculeogenin as an active ingredient is preferably one specified for use as "for reducing the risk of, preventing, or improving diseases or conditions such as elevated blood cholesterol, arteriosclerosis, muscle atrophy, depression, rough skin, etc."
[0106] Therefore, the aglycone of a steroid alkaloid glycoside (e.g., tomatidine) produced by the method of the present invention and a composition containing aglycone of a steroid alkaloid glycoside (e.g., a composition containing tomatidine) can be used as is, or by mixing with appropriate ingredients as necessary, in foods and beverages, cosmetics, pharmaceuticals, etc.
[0107] That is, according to the present invention, there is provided a food, drink, cosmetic, or pharmaceutical product comprising a composition containing the aglycone (e.g., tomatidine, esculeogenin) of the above-mentioned steroid alkaloid glycoside. Here, "comprises" means that it may contain a physiologically acceptable carrier or additive according to the desired product form, and also means that it contains other auxiliary components that can be used in combination. Hereinafter, the carrier, additive, and auxiliary component may be referred to as "other components".
[0108] The food, beverage, cosmetic, or pharmaceutical product of the present invention containing the aglycone of a steroid alkaloid glycoside as an active ingredient is preferably one specified for use as "for reducing the risk of, preventing, or improving diseases or conditions such as elevated blood cholesterol, arteriosclerosis, muscle atrophy, depression, rough skin, etc."
[0109] In the present invention, the term "food and drink" refers to any food or drink other than pharmaceuticals that can be orally ingested, and is not particularly limited thereto. Specific examples include instant foods, such as solid, powder, liquid, gel, and slurry foods, beverages, confectioneries, seasonings, dairy products, processed livestock products, processed agricultural products, frozen foods, and the like.
[0110] The foods and beverages include health foods (e.g., functional foods, nutritional supplements, health supplements, nutritionally fortified foods, nutritionally regulated foods, supplements, etc.), health functional foods (e.g., foods for specified health uses, nutritionally functional foods, foods with functional claims, etc.), foods for special dietary uses (e.g., foods for the sick, infant formula, milk powder for pregnant or lactating women, etc.), as well as categories such as foods and beverages that are labeled to reduce the risk of developing a disease or condition (symptoms) or to prevent or ameliorate a disease or condition (symptoms) by administration of an aglycone of a steroid alkaloid glycoside, such as tomatidine or esculeogenin.
[0111] When used as a food or beverage, other ingredients may include various oils and fats, herbal medicines, amino acids, polyhydric alcohols, natural polymers, vitamins, dietary fiber, surfactants, purified water, excipients, stabilizers, pH adjusters, antioxidants, sweeteners, taste components, acidulants such as organic acids, stabilizers, flavors, colorants, fragrances, etc.
[0112] In the present invention, the term "cosmetics" refers to cosmetics including quasi-drugs (medicinal cosmetics), and may take a wide variety of forms, such as aqueous solutions, solubilized solutions, emulsions, powders, oils, gels, ointments, aerosols, etc. Specific examples include skin care products such as emulsions, creams, and lotions, and hair cosmetics.
[0113] When used as cosmetics, other ingredients may include, for example, preservatives, antioxidants, physiologically active ingredients, extract ingredients derived from animals, seaweed, microorganisms, and plants, fragrances, powders, amino acids, pigments, natural vitamins, etc.
[0114] In the present invention, a pharmaceutical product is prepared as an oral or parenteral formulation in accordance with a conventional method by combining with other ingredients such as additives that are acceptable for formulation. In the case of an oral formulation, there is no particular limitation as long as it is in a form that can be taken orally. In the case of a parenteral formulation, it can be in the form of an injection or suppository. From the viewpoint of simplicity, an oral formulation is preferable.
[0115] Examples of other components such as additives that are acceptable for formulation include herbal medicines, vitamins, minerals, etc., as well as excipients, surfactants, coating agents, oils and fats, stabilizers, preservatives, humectants, emulsifiers, lubricants, sweeteners, colorants, flavorings, buffers, antioxidants, pH adjusters, acidulants such as citric acid, malic acid, and gluconic acid.
[0116] According to another aspect of the present invention, there is provided a food or beverage comprising the tomatidine or tomatidine-containing composition of the present invention, the food or beverage being indicated to show that a disease or condition is prevented or ameliorated by administration of tomatidine.
[0117] The content of the aglycone of the steroid alkaloid glycoside (e.g., tomatidine) which is the active ingredient contained in the food, beverage, cosmetic or pharmaceutical of the present invention is difficult to uniformly define due to its type, form, use, etc., but is, for example, about 0.01 to 34 mg, preferably 0.1 to 17 mg, more preferably about 1 to 10 mg. Furthermore, the content of the active ingredient in the food, beverage, cosmetic or pharmaceutical may be appropriately set in consideration of the daily intake of the active ingredient so that the necessary amount of the active ingredient per day can be ingested (applied or taken). In addition, when the active ingredient is esculeogenin, the content of esculeogenin in the food, beverage, cosmetic or pharmaceutical may be appropriately set in consideration of the daily intake of esculeogenin, as described above. EXAMPLES
[0118] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the following examples.
[0119] [Example 1] Freeze-dried powder The stems were removed from 7,497.44 g of unripe tomatoes, which were then frozen overnight at -80°C, freeze-dried for one week, and crushed in a grinder to obtain 503.33 g of freeze-dried powder of unripe tomatoes (solid content 6.71%).
[0120] [Example 2] Sugar utilization test Tomatine is a compound in which one galactose, two glucose, and one xylose are bound to tomatidine (compound represented by formula (I)). In order to produce tomatidine from tomatine, these sugars must be cleaved by hydrolysis.
[0121] 52.2 g of MRS broth (Merck, all products below are from the same company) was weighed out and dissolved in 1,000 ml of pure water. 5 ml portions were dispensed, sterilized by high-pressure steam at 121°C for 15 minutes, and cooled to room temperature. Eighteen in-house strains (Figure 2) stored frozen at -80°C were naturally thawed, and 0.5 ml of each strain was inoculated into 5 ml of MRS broth and cultured at 35°C for 48 hours.
[0122] The test bacteria were inoculated into MRS broth and cultured at 35°C for 72 hours. After the culture, centrifugation (4°C, 1,800 rpm, 15 minutes) was performed, and the supernatant was removed. 5 ml of sterile saline was added to the bacteria, the bacteria were suspended, centrifuged (4°C, 1,800 rpm, 10 minutes), and the supernatant was removed. 5 ml of sterile saline was added again to the bacteria, the bacteria were suspended, and centrifuged (4°C, 1,800 rpm, 10 minutes), the supernatant was removed, and 2 ml of sterile saline was added to the bacteria to suspend them.
[0123] To 800 ml of pure water, 2.0 g of proteose peptone, 1.5 g of yeast extract, 1 ml of Tween 20, 5.0 g of sodium acetate pentahydrate, 0.492 g of magnesium sulfate heptahydrate, 2.0 g of potassium dihydrogen phosphate, 0.8 g of manganese sulfate pentahydrate, 0.22 g of bromocresol purple (BCP), and 40 ml of 0.3 M phosphate buffer, pH 7.5 were added, stirred, and diluted with pure water to 1000 ml (hereinafter referred to as "BCP-added substrate culture solution").
[0124] BCP-added substrate culture medium, 0.4% glucose aqueous solution, 0.4% galactose aqueous solution, and 0.4% xylose aqueous solution were each prepared and sterilized by high-pressure steam at 121°C for 15 minutes. After that, the BCP-added substrate culture medium and 0.4% glucose aqueous solution were mixed in a 1:1 ratio (hereinafter sometimes referred to as "0.4% glucose-added substrate culture medium"), the BCP-added substrate culture medium and 0.4% galactose aqueous solution were mixed in a 1:1 ratio (hereinafter sometimes referred to as "0.4% galactose-added substrate culture medium"), and the BCP-added substrate culture medium and 0.4% xylose aqueous solution were mixed in a 1:1 ratio (hereinafter sometimes referred to as "0.4% xylose-added substrate culture medium").
[0125] 120 μl of BCP-added substrate culture solution was dispensed to A1 to H1 of the 96-well microplate, and 175 μl of 0.4% glucose-added substrate culture solution was dispensed to A2 to H2, A3 to H3, and A4 to H4. 175 μl of 0.4% galactose-added substrate culture solution was dispensed to A5 to H5, A6 to H6, and A7 to H7 of the microplate. 175 μl of 0.4% xylose-added substrate culture solution was dispensed to A8 to H8, A9 to H9, and A10 to H10 of the microplate. 120 μl of sugar-free substrate culture solution was dispensed to G11 of the microplate, and 175 μl of 0.4% glucose-added substrate culture solution was dispensed to D11 to F11 of the microplate. Further, 175 μl of 0.4% galactose-added substrate culture solution was dispensed to each of A11 to C11 of the microplates. Further, 175 μl of 0.4% xylose-added substrate culture solution was dispensed to each of A12 to C12 of the microplates. Further, 100 μl of BCP-added substrate culture solution was dispensed to each of H11 and D12 to H12 of the microplates.
[0126] The bacterial liquid was thoroughly suspended, and 130 μl of each was added to A1 to H1 and G11 of the microplate, and the mixture was stirred by pipetting 10 times (hereinafter, sometimes referred to as "mixture"). The mixture of A1 was dispensed to A2 to A10, the mixture of B1 to B2 to B10, the mixture of C1 to C2 to C10, the mixture of D1 to D2 to D10, the mixture of E1 to E2 to E10, the mixture of F1 to F2 to F10, the mixture of G1 to G2 to G10, the mixture of H1 to H2 to H10, and the mixture of G11 to A11 to F11 and A12 to C12, each in an amount of 25 μl. Sterile saline was dispensed to H11 and D12 to H12 of the microplate, in an amount of 100 μl each.
[0127] Using a multispectro microplate reader (Thermo), the absorbance at 0 hours of culture was measured at two wavelengths, a measurement wavelength of 405 nm and a control wavelength of 655 nm, and 10 ml of pure water was placed in a 50 ml glass beaker, placed in a square jar, and Anaeropack (Mitsubishi Gas Chemical Co., Ltd.) was added, the lid was placed, and the mixture was cultured anaerobic for 72 hours at 35°C. After culture, the absorbance at 72 hours of culture was measured at two wavelengths, a measurement wavelength of 405 nm and a control wavelength of 655 nm, using a multispectro microplate reader (Thermo).
[0128] The score was calculated using the following formula. Calculation formula: score = absorbance at 405 nm (72 hours of culture - 0 hours of culture) - absorbance at 665 nm (72 hours of culture - 0 hours of culture). A score of 0.7 or more was evaluated as ++, 0.4 to less than 0.7 as +, 0.2 to less than 0.4 as ±, and less than 0.2 as - (Figure 2).
[0129] We discovered the possibility of producing tomatidine from tomatine by co-culturing Pediococcus Pentosaceus NB17, which has glucose assimilation rate ++ and galactose assimilation rate ++ and whose strain has been identified, with Levilactobacillus sp. NC4, the only strain that had xylose assimilation rate ++.
[0130] [Example 3] 0-72 hour culture test of NB17, NC4, and a mixture of NB17 and NC4 52.2 g of MRS broth was weighed and dissolved in 1,000 ml of pure water. 5 ml of each was dispensed, sterilized by high-pressure steam at 121°C for 15 minutes, and cooled to room temperature. Pediococcus Pentosaceus NB17 and Levilactobacillus sp. NC4, which had been frozen and stored at -80°C, were naturally thawed, and 0.5 ml of each was inoculated into 5 ml of MRS broth and cultured at 35°C for 24 hours. After culture, centrifugation (4°C, 1,800 rpm, 15 minutes) was performed and the supernatant was removed. 5 ml of sterile saline was added and suspended, and centrifugation (4°C, 1,800 rpm, 10 minutes) was performed and the supernatant was removed. 5 ml of sterile saline was added again and suspended, and centrifugation (4°C, 1,800 rpm, 10 minutes) was performed and the supernatant was removed, and 2 ml of sterile saline was added and suspended in the finally obtained bacterial cells.
[0131] Three 100ml bottles of medium were prepared, and 4g of freeze-dried powder of unripe tomatoes was placed in each bottle, and 95ml of boiled pure water was added to suspend the mixture. The mixture was sterilized by heating at 80℃ for 30 minutes, cooled to room temperature, and adjusted to pH 6.5 with 5M NaOH. 1ml of Pediococcus Pentosaceus NB17, 1ml of Levilactobacillus sp. NC4, 0.5ml of Pediococcus Pentosaceus NB17, and 0.5ml of Levilactobacillus sp. NC4 were added to each bottle, and the mixture was cultured at 35℃ for 72 hours with stirring. Sampling was performed at 0, 24, 48, and 72 hours of culture, and pH and tomatidine content were measured.
[0132] The pH dropped to below 4.5 within 24 hours, and even after culturing for 72 hours, the pH only changed by 0.5 or less, reaching a plateau within 24 hours (Figure 3).
[0133] It was confirmed that the tomatidine content peaked at 24 hours and then decreased after 48 hours (Figure 4). After 24 hours of cultivation, the tomatidine content per 100 g of freeze-dried powder of unripe tomatoes was 2242.84 mg for Pediococcus Pentosaceus NB17 alone, 2353.65 mg for Levilactobacillus sp. NC4 alone, and 2470.58 mg for a mixture of Pediococcus Pentosaceus NB17 and Levilactobacillus sp. NC4, indicating that mixed cultivation results in synergistic production of tomatidine.
[0134] [Example 4] 0-48 hour culture test of mixed bacteria of NB17 and NC4 52.2 g of MRS broth was weighed and dissolved in 1,000 ml of pure water. 5 ml of each was dispensed, sterilized by high-pressure steam at 121°C for 15 minutes, and cooled to room temperature. Pediococcus Pentosaceus NB17 and Levilactobacillus sp. NC4, which had been frozen and stored at -80°C, were naturally thawed, and 0.5 ml of each was inoculated into 5 ml of MRS broth and cultured at 35°C for 24 hours. After culture, centrifugation (4°C, 1,800 rpm, 15 minutes) was performed and the supernatant was removed. 5 ml of sterile saline was added and suspended, and centrifugation (4°C, 1,800 rpm, 10 minutes) was performed and the supernatant was removed. 5 ml of sterile saline was added again and suspended, and centrifugation (4°C, 1,800 rpm, 10 minutes) was performed and the supernatant was removed, and 2 ml of sterile saline was added and suspended in the finally obtained bacterial cells.
[0135] 3.2g of freeze-dried powder of unripe tomatoes was placed in a 100ml medium bottle and suspended in 76ml of boiled pure water. The mixture was sterilized by heating at 80℃ for 30 minutes, cooled to room temperature, and adjusted to pH 6.5 with 2M NaOH. 0.4ml of Pediococcus Pentosaceus NB17 (FERM P-20897) and 0.4ml of Levilactobacillus sp. NC4 (NITE P-03879) were added, and the mixture was cultured at 35℃ for 48 hours with stirring. Sampling was performed at 0, 8, 16, 24, 32, 40, and 48 hours of culture, and the pH and tomatidine content were measured.
[0136] The pH dropped to below 4.5 in 16 hours, and even after culturing for 48 hours, the change in pH was below 0.5, and the pH had almost plateaued at 16 hours (Figure 5).
[0137] The tomatidine content peaked after 8 hours of culture and then decreased, but remained stable at a relatively high level from 16 to 32 hours, and was confirmed to decrease after 40 hours (Figure 6).
[0138] It was found that the optimal conditions for cultivation were from 16 hours onwards, when the lactic acid bacteria culture reached a steady state, and from 16 to 32 hours, when the tomatidine content stabilized.
[0139] [Example 5] Culture dry matter and its tomatidine content 52.2 g of MRS broth was weighed and dissolved in 1,000 ml of pure water. 5 ml of each was dispensed, sterilized by high-pressure steam at 121°C for 15 minutes, and cooled to room temperature. Pediococcus Pentosaceus NB17 and Levilactobacillus sp. NC4, which had been frozen and stored at -80°C, were naturally thawed, and 0.5 ml of each was inoculated into 5 ml of MRS broth and cultured at 35°C for 24 hours. After culture, centrifugation (4°C, 1,800 rpm, 15 minutes) was performed and the supernatant was removed. 5 ml of sterile saline was added and suspended, and centrifugation (4°C, 1,800 rpm, 10 minutes) was performed and the supernatant was removed. 5 ml of sterile saline was added again and suspended, and centrifugation (4°C, 1,800 rpm, 10 minutes) was performed and the supernatant was removed, and 2 ml of sterile saline was added and suspended in the finally obtained bacterial cells.
[0140] 3.8 g of freeze-dried powder of unripe tomatoes was placed in a 100 ml medium bottle and suspended in 90 ml of boiled pure water. The mixture was sterilized by heating at 80 for 30 minutes, cooled to room temperature, and then adjusted to pH 6.5 with 2 M NaOH. 0.5 ml of Pediococcus Pentosaceus NB17 and 0.5 ml of Levilactobacillus sp. NC4 were added, and the mixture was cultured with stirring at 35 for 24 hours. After culture, the entire amount was freeze-dried and the tomatidine content was measured, yielding 3.38 g of freeze-dried powder of unripe tomatoes containing 3.38% tomatidine.
[0141] [Example 6] Measurement of lactic acid bacteria count 24.7 g of BCP-added plate count agar (manufactured by Nissui Pharmaceutical Co., Ltd.) was weighed out and suspended in 1,000 ml of pure water. The mixture was sterilized by high-pressure steam at 121°C for 15 minutes and kept warm at 50°C. 0.5 g of the powder of Example 5 was weighed out and suspended in 4.5 ml of sterile saline, and then serially diluted with sterile saline (hereinafter sometimes referred to as "diluted solutions"). 1 ml of each diluted solution was added to a 90 mm petri dish, 20 ml of BCP-added plate count agar kept at 50°C was added, and the mixture was gently stirred and dried. The mixture was placed in a square jar, Anaeropack (manufactured by Mitsubishi Gas Chemical Co., Ltd.) was added, and the mixture was anaerobic-cultured at 35°C for 72 hours, after which colony counting was performed.
[0142] The powder of Example 5 contained 8.2 × 10 Pediococcus Pentosaceus NB17 and Levilactobacillus sp. NC4. 9 It was confirmed that it contains 1000 pieces / g.
[0143] [Example 7] Dextrin blending test 52.2 g of MRS broth was weighed out and dissolved in 1,000 ml of pure water. 5 ml portions were dispensed, autoclaved at 121°C for 15 minutes, and cooled to room temperature. Pediococcus Pentosaceus NB17 and Levilactobacillus sp. NC4, which had been frozen and stored at -80°C, were naturally thawed, and 0.5 ml of each was inoculated into 5 ml of MRS broth and cultured at 35°C for 24 hours. After culture, 1 ml of each was inoculated into 20 ml of MRS broth and cultured at 35°C for 24 hours. After culture, the entire amount was mixed to obtain 40 ml of lactic acid bacteria liquid.
[0144] 80 g of freeze-dried powder of unripe tomatoes was weighed out and suspended in 1,900 ml of pure water heated to 80°C. The mixture was sterilized by heating at 80°C for 30 minutes, cooled to room temperature, and adjusted to pH 6.5 with 5M NaOH. 20 ml of lactic acid bacteria liquid was added and cultured with stirring at 35°C for 24 hours. After cultivation, the mixture was roughly filtered through nonwoven fabric.
[0145] The mixture was divided into three portions of 500 ml each, and dextrin was added to each portion so as to make the concentration 0%, 33%, and 50%, respectively, and the mixture was spray-dried using a spray dryer SD-1000 (manufactured by EYELA).
[0146] It was found that powder could not be recovered from 0% dextrin, but the same amount of powder could be recovered from 33% and 50% dextrin, and that powderization was not possible unless at least dextrin was added. Furthermore, moisture absorption occurred during storage at 33%, but was suppressed at 50%, and it was found that the higher the dextrin ratio in the tomatidine-containing composition, the more stable the product became.
[0147] [Example 8] Preparation of tomatidine by heating 4 g of freeze-dried powder of unripe tomatoes was placed in a 100 ml bottle, and 95 ml of boiled pure water was added to suspend it. It was heated to 80°C, and samples were taken after 30 and 60 minutes. After cooling to room temperature, the tomatidine content was measured.
[0148] It was confirmed that tomatidine increased in a time-dependent manner at 30 and 60 minutes, and after 60 minutes of heating, the amount produced was the same as that after 24 hours of culture in Examples 3 and 4 (FIG. 7).
[0149] [Example 9] HPLC analysis method Tomatidine was analyzed by high performance liquid chromatography (HPLC) under the following conditions to measure the tomatidine content.
[0150] Equipment: Prominence series (Shimadzu) Column: Inertsil NH2 (250 x 4.0 mm, id, 5 μm) Column temperature: 20℃ Mobile phase: Acetonitrile / 1 mM potassium dihydrogen phosphate, composition (volume ratio) 96 / 4 Flow rate: 1ml / min Detection wavelength: 208 nm
[0151] Creating a calibration curve 10 mg of tomatidine (CAS: 6192-62-7, FW: 452.10, ≧90%) was weighed and placed in a 15 ml centrifuge tube. 10 ml of methanol was added to dissolve (1000 μg / ml). The solution was diluted to 100 μg / ml and 10 μg / ml using methanol. The solution was passed through a 0.45 μm filter and subjected to HPLC (FIG. 8).
[0152] Measurement of specimens In Examples 3, 4, and 8, 10 ml of the sampled specimen was taken, and in Example 5, 200 mg of the freeze-dried powder obtained was dissolved in 9.8 ml of pure water. The pH was adjusted to 8.5 or higher with 5 M sodium hydroxide, centrifuged at 4000 rpm for 10 minutes, and the supernatant was discarded. 10 ml of 70% aqueous ethanol was added and suspended, and then stirred for 1 minute. The mixture was centrifuged at 4000 rpm for 10 minutes, and the supernatant was discarded. 8 ml of methanol was added and suspended, and then stirred for 1 minute. The mixture was made up to 10 ml with methanol, and centrifuged at 4000 rpm for 10 minutes. The supernatant was collected, passed through a 0.45 μm filter, and subjected to HPLC. The measurement results are as shown in the above examples.
Claims
1. A method for producing an aglycone of a steroid alkaloid glycoside, comprising acting a lactic acid bacterium or a processed product thereof, which has the ability to convert a steroid alkaloid glycoside into its aglycone, on a steroid alkaloid glycoside to produce the aglycone.
2. 2. The method according to claim 1, wherein the steroidal alkaloid glycoside is tomatine and the aglycone of the steroidal alkaloid glycoside is tomatidine.
3. 3. The method according to claim 1, wherein the lactic acid bacteria is either or both of lactic acid bacteria belonging to the genus Pediococcus or lactic acid bacteria belonging to the genus Levilactobacillus.
4. A composition comprising either live or killed lactic acid bacteria or both of the bacteria having the ability to convert a steroid alkaloid glycoside into its aglycone, and the aglycone of a steroid alkaloid glycoside.
5. The steroid alkaloid glycoside is tomatine, the aglycone of the steroid alkaloid glycoside is tomatidine, the content of the tomatidine in the composition is 0.01 to 10% or more in terms of dry mass, and the content of lactic acid bacteria in the composition is 1 x 10 per 1 g of dry mass. 13 ~1×10 6 The composition of claim 4 .
6. The composition according to claim 4, wherein the lactic acid bacteria are either or both of lactic acid bacteria belonging to the genus Pediococcus or lactic acid bacteria belonging to the genus Levilactobacillus.
7. A food, drink, cosmetic or pharmaceutical product comprising the composition according to any one of claims 4 to 6.
8. A method for producing tomatidine, comprising heating processed tomatoes in an aqueous medium without adding an acid.
9. The Leviractobacillus sp. NC4 strain is deposited under the accession number NITE P-03879.
Citation Information
Patent Citations
Vertical recirculation parking apparatus
JP1986075172A
Prophylactic and therapeutic agent of arteriosclerosis
JP2009209099A
Production method of tomatidine
JP2018184394A
Methods of making tomatidine or esculeogenin and products using tomatidine or esculeogenin
JP2019210236A
Composition for preventing, treating and / or mitigating depressive symptom, and composition for increasing momentum
JP2022053441A
